Gluconeogenesis (abbreviated GNG) is a metabolic pathway that results in the generation of glucose from non-carbohydrate carbon substrates such as lactate, glycerol, and glucogenic amino acids.
As liver cancer develops, tumor cells lose the ability to produce and release glucose into the bloodstream, a key function of healthy liver cells for maintaining needed blood-sugar levels.
Activation of mu-opioid receptors in the nerves of the portal vein walls triggers a gut–brain neural circuit that leads to feelings of satiety, researchers report in Cell.
Frequently recommended in weight-loss diets, dietary proteins have proven effectiveness thanks to their appetite-suppressing effects. A team led by Gilles Mithieux, Director of Inserm's Unit 855 "Nutrition and the Brain" in Lyon, has managed to explain the biological mechanisms behind these properties.
A uniquely collaborative study by researchers at the Salk Institute for Biological Studies uncovered a novel mechanism that turns up glucose production in the liver when blood sugar levels drop, pointing towards a new class of drugs for the treatment of metabolic disease.
Biologists have found that a key protein that regulates the biological clocks of mammals also regulates glucose production in the liver and that altering the levels of this protein can improve the health of diabetic mice.
Tuberculosis (TB) has been present in humans since ancient times. The origins of the disease date back to the first domestication of cattle, and skeletal remains show prehistoric humans (4,000 B.C.) had TB. Although relatively rare in the United States, it is the single leading bacterial cause of death worldwide. Approximately 8 million people are infected each year and 2 million people die from TB.
MSGI Security Solutions Inc. (OTCBB: MSGI) today reported that the Company is launching its first product derived from NASA technology, a handheld test for Diabetes, which uses breath instead of blood.
Obesity is probably the most important factor in the development of insulin resistance, but science's understanding of the chain of events is still spotty. Now, researchers at the Salk Institute for Biological Studies have filled in the gap and identified the missing link between the two.
Researchers have discovered a factor that controls blood sugar's manufacture in a novel way: by limiting the supply of its building blocks. The findings are reported in the April issue of the journal Cell Metabolism, published by Cell Press.
In many patients with type 2 diabetes, the liver acts like a sugar factory on overtime, churning out glucose throughout the day, even when blood sugar levels are high. Scientists at the Salk Institute for Biological Studies discovered a key cellular switch that controls glucose production in liver cells.
Metabasis Therapeutics and Merck announced today that they have formed a collaboration to research, develop and commercialize novel small molecule therapeutics with potential to treat several diseases, including type II diabetes, hyperlipidemia and obesity, by activation of an enzyme in the liver called AMP-activated Protein Kinase (AMPK).
Scientists from MitoChroma Research have recently announced a patent-pending discovery that could complement current medical management modalities for Type 2 Diabetes, insulin resistance and the set of related conditions called "Metabolic Syndrome."